Abstract | INTRODUCTION:
Stenosis, mediated by neointimal hyperplasia and thrombosis, is a major limiting factor in successful stent implantation. The introduction of a stent, coated in its endoluminal surface by antihuman CD34 antibodies with endothelial progenitor cell-capturing properties, opens the possibility of promoting a rapid and normal functioning coverage by endothelium and thus avoids both an excessive cell proliferation within stent and the need for long-term dual antiplatelet therapy. These stents, developed for adult coronary artery disease, have not yet been implanted in children or in those with congenital heart disease. OBJECTIVE AND METHODS: RESULTS: To maintain the patency of two modified Blalock-Taussig shunts and one ductus arteriosus, four Genous® stents were implanted in three infants with cyanotic heart disease. All procedures were immediately successful, with resolution of stenosis and improvement in transcutaneous oxygen saturation from 66% ± 3.6% to 92% ± 2.6%. In the follow-up, one stent had no occlusion; however, the remaining two had partial occlusion after 5 and 5.5 months, which were successfully managed with balloon dilatation preceding elective definitive surgical correction. CONCLUSION: In our preliminary experience, we demonstrated that Genous® stent implantation was feasible in infants with complex congenital heart disease. Additional studies with larger samples and longer follow-up are required to confirm the potential benefits of this technology in this clinical setting.
|
Authors | Nuno Cabanelas, José D F Martins, Fátima Pinto |
Journal | Cardiology in the young
(Cardiol Young)
Vol. 24
Issue 5
Pg. 900-4
(Oct 2014)
ISSN: 1467-1107 [Electronic] England |
PMID | 24044550
(Publication Type: Case Reports, Journal Article)
|
Chemical References |
- Antibodies
- Antigens, CD34
|
Topics |
- Antibodies
(pharmacology)
- Antigens, CD34
(immunology)
- Blalock-Taussig Procedure
(instrumentation)
- Cardiac Catheterization
(methods)
- Drug-Eluting Stents
- Embolic Protection Devices
- Endothelial Progenitor Cells
(immunology)
- Feasibility Studies
- Female
- Heart Defects, Congenital
(surgery)
- Humans
- Infant, Newborn
- Male
- Prosthesis Design
- Thrombosis
(etiology, prevention & control)
- Treatment Outcome
|